An insurance benefit that provides percutaneous coronary intervention patients with a discharge supply of antiplatelet medication could result in cost savings for insurers.
Michael P. Dorsch, PharmD, MS
Advertisement
Articles by Michael P. Dorsch, PharmD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
2
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
3
Counseling Vitiligo Patients on Time to Repigmentation
4
5 August FDA Approvals Marked by Novelty, Pushback
5